Shares of MacroGenics Inc (NASDAQ:MGNX) have earned an average rating of “Buy” from the seventeen ratings firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $22.83.

Several research firms have issued reports on MGNX. Zacks Investment Research upgraded shares of MacroGenics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Thursday, January 9th. Morgan Stanley lowered shares of MacroGenics from an “equal” rating to an “equal weight” rating and cut their price target for the company from $17.00 to $6.00 in a research report on Thursday, November 21st. Nomura restated a “buy” rating and set a $50.00 price target on shares of MacroGenics in a research report on Thursday, December 12th. Guggenheim began coverage on shares of MacroGenics in a research report on Wednesday, November 20th. They set a “hold” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of MacroGenics in a research report on Friday, December 20th.

NASDAQ:MGNX traded down $0.33 during midday trading on Friday, hitting $11.26. The company had a trading volume of 401,194 shares, compared to its average volume of 555,400. MacroGenics has a 52-week low of $7.43 and a 52-week high of $32.32. The stock’s fifty day moving average price is $10.55 and its 200-day moving average price is $12.10. The company has a market capitalization of $551.27 million, a PE ratio of -2.69 and a beta of 2.31. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.11.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.03. MacroGenics had a negative net margin of 303.08% and a negative return on equity of 59.67%. The company had revenue of $18.74 million during the quarter, compared to analyst estimates of $23.33 million. As a group, research analysts forecast that MacroGenics will post -3.4 earnings per share for the current year.

Several large investors have recently modified their holdings of the company. Stifel Financial Corp raised its stake in shares of MacroGenics by 4.9% during the third quarter. Stifel Financial Corp now owns 20,287 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 950 shares during the last quarter. Metropolitan Life Insurance Co NY raised its stake in shares of MacroGenics by 23.4% during the third quarter. Metropolitan Life Insurance Co NY now owns 16,259 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 3,081 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of MacroGenics during the first quarter valued at about $59,000. Morgan Stanley raised its stake in shares of MacroGenics by 7.1% during the second quarter. Morgan Stanley now owns 50,602 shares of the biopharmaceutical company’s stock valued at $859,000 after acquiring an additional 3,358 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in shares of MacroGenics by 3.6% during the second quarter. Victory Capital Management Inc. now owns 106,600 shares of the biopharmaceutical company’s stock valued at $1,809,000 after acquiring an additional 3,670 shares during the last quarter. 94.92% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Featured Article: What do I need to know about analyst ratings?

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.